Molecular Imaging As A Critical Tool In Discovery Of The Basis Of Tumour Heterogeneity And Developing Novel Therapies To Overcome Therapeutic Resistance
Grant number: 1108050 | Funding period: 2016 - 2020
Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. However, this approach fails to recognise the ability of tumours to evolve components that are, or become, resistant to treatment. My laboratory uses advanced molecular imaging, targeted biopsies, animal models and genetic analysis to detect and understand the basis of such resistance and thereby develop new, targeted treatments to improve patient outcomes.
Related publications (18)
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Scott G Williams, Rodney J Hicks, Michael S Hofman
BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) ..
The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma
Grace Kong, Tess Schenberg, Christopher J Yates, Alison Trainer, Nirupa Sachithanandan, Amir Iravani, Aravind Ravi Kumar, Michael S Hofman, Tim Akhurst, Michael Michael, Rodney J Hicks
Purpose: Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and requ..
PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment
Amir Iravani, Guy-Anne Turgeon, Tim Akhurst, Jason W Callahan, Mathias Bressel, Sarah J Everitt, Shankar Siva, Michael S Hofman, Rodney J Hicks, David L Ball, Michael P Mac Manus
Cu-64-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy
Rodney J Hicks, Price Jackson, Grace Kong, Robert E Ware, Michael S Hofman, David A Pattison, Timothy A Akhurst, Elizabeth Drummond, Peter Roselt, Jason Callahan, Roger Price, Charmaine M Jeffery, Emily Hong, Wayne Noonan, Alan Herschtal, Lauren J Hicks, Amos Hedt, Matthew Harris, Brett M Paterson, Paul S Donnelly
Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework
Hayley M Reynolds, Scott Williams, Price Jackson, Catherine Mitchell, Michael S Hofman, Rodney J Hicks, Declan G Murphy, Annette Haworth
Dosimetry of Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J Hicks, Michael S Hofman
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Kaiji Fan, Cathrin Ritter, Paul Nghiem, Astrid Blom, Monique E Verhaegen, Andrzej Dlugosz, Niels Odum, Anders Woetmann, Richard W Tothill, Rodney J Hicks, Michael Sand, David Schrama, Dirk Schadendorf, Selma Ugurel, Juergen C Becker